Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.66 |
| ▸ | RARG | P13631 | 10/20 | 0.66 |
| ▸ | RARA | P10276 | 8/20 | 0.66 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | BLVRB | P30043 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 13/20 | 0.62 |
| ▸ | RXRB | P28702 | 9/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569037 | 1.00 | RARB (0.66) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL30942550 | 0.87 | CYP3A4 (0.68) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9319350 | 0.85 | CYP26A1 (0.71) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8458958 | 0.82 | RXRA (0.69) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19072651 | 0.80 | CYP3A4 (0.63) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL846110 | 0.80 | RARB (0.81) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29827631 | 0.80 | RARB (0.81) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29355626 | 0.80 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL726740 | 0.80 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9318594 | 0.80 | RXRA (0.70) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5338749-A | Treating rheumatic or arthritic disorders | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| EP-0386451-B1 | OXYGEN-BEARING DIPHENYL HETEROALKANES, PROCESS FOR THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1993-04-28 | — | — | EP | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5128479-A | Skin disorders, cosmetics | BASF AKTIENGESELLSCHAFT (DE) | 1992-07-07 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
| EP-0386451-A1 | Oxygen-bearing diphenyl heteroalkanes, process for their preparation and use | BASF Aktiengesellschaft (DE) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARB 987/4885RARG 744/4885RARA 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.